Ptc Therapeutics (PTCT) Total Debt (2012 - 2026)

Ptc Therapeutics' Total Debt history runs 15 years deep, the most recent figure standing at $305.0 million for Q1 2026.

• In Q1 2026, Total Debt fell 42.87% year-over-year to $305.0 million; the TTM figure through Mar 2026 stood at $305.0 million (down 42.87% YoY), while the FY2025 annual figure was $286.6 million, down 47.24% from the prior year.
• Total Debt was $305.0 million for Q1 2026 at Ptc Therapeutics, up from $286.6 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $679.0 million in Q3 2023 to a low of $260.6 million in Q3 2025.
• Historically, Total Debt has averaged $492.1 million across 5 years, with a median of $534.0 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Total Debt soared 90.27% in 2023, then sank 51.98% in 2025.
• A 5-year view of Total Debt shows it stood at $643.9 million in 2022, then fell by 25.68% to $478.5 million in 2023, then rose by 13.52% to $543.2 million in 2024, then sank by 47.24% to $286.6 million in 2025, then rose by 6.42% to $305.0 million in 2026.
• The last three Total Debt figures came in at $305.0 million (Q1 2026), $286.6 million (Q4 2025), and $260.6 million (Q3 2025), per Business Quant data.